Imbalance of TGF-β1/BMP-7 Pathways Induced by M2-polarized Macrophages Promotes Hepatocellular Carcinoma Aggressiveness
Overview
Pharmacology
Authors
Affiliations
The transforming growth factor-beta (TGF-β) signaling pathway is the predominant cytokine signaling pathway in the development and progression of hepatocellular carcinoma (HCC). Bone morphogenetic protein (BMP), another member of the TGF-β superfamily, has been frequently found to participate in crosstalk with the TGF-β pathway. However, the complex interaction between the TGF-β and BMP pathways has not been fully elucidated in HCC. We found that the imbalance of TGF-β1/BMP-7 pathways was associated with aggressive pathological features and poor clinical outcomes in HCC. The induction of the imbalance of TGF-β1/BMP-7 pathways in HCC cells could significantly promote HCC cell invasion and stemness by increasing inhibitor of differentiation 1 (ID1) expression. We also found that the microRNA (miR)-17-92 cluster, originating from the extracellular vesicles (EVs) of M2-polarized tumor-associated macrophages (M2-TAMs), stimulated the imbalance of TGF-β1/BMP-7 pathways in HCC cells by inducing TGF-β type II receptor (TGFBR2) post-transcriptional silencing and inhibiting activin A receptor type 1 (ACVR1) post-translational ubiquitylation by targeting Smad ubiquitylation regulatory factor 1 (Smurf1). In vivo, short hairpin (sh)-MIR17HG and ACVR1 inhibitors profoundly attenuated HCC cell growth and metastasis by rectifying the imbalance of TGF-β1/BMP-7 pathways. Therefore, we proposed that the imbalance of TGF-β1/BMP-7 pathways is a feasible prognostic biomarker and recovering the imbalance of TGF-β1/BMP-7 pathways might be a potential therapeutic strategy for HCC.
Prospect of extracellular vesicles in tumor immunotherapy.
Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.
PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.
Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment.
Jiang H Cancer Manag Res. 2025; 17:219-237.
PMID: 39912095 PMC: 11796448. DOI: 10.2147/CMAR.S495169.
Zhang S, Xing Z, Ke J J Bone Oncol. 2025; 50():100655.
PMID: 39850453 PMC: 11755076. DOI: 10.1016/j.jbo.2024.100655.
Yang X, Chen N, Wen Q, Zhou Y, Zhang T, Zhou J J Transl Med. 2025; 23(1):61.
PMID: 39806464 PMC: 11727790. DOI: 10.1186/s12967-024-05950-w.
Zhang Q, Liu X, Wei Q, Xiong S, Luo W, Zhou Y Redox Biol. 2025; 80:103485.
PMID: 39756316 PMC: 11758215. DOI: 10.1016/j.redox.2024.103485.